Atyr pharma presents preclinical data for nrp2-targeting antibody atyr2810 at the american association for cancer research (aacr) annual meeting 2025

San diego, april 29, 2025 (globe newswire) -- atyr pharma, inc. (nasdaq: atyr) (“atyr” or the “company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary trna synthetase platform, today announced that the company will present a poster featuring preclinical data for atyr2810, a monoclonal antibody targeting neuropilin-2 (nrp2), at the american association for cancer research (aacr) annual meeting 2025, which is being held april 25 – 30, 2025, in chicago, il. “aggressive cancers like glioblastoma multiforme (gbm) continue to show drug resistance, and the efficacy of current immunotherapies may be limited due to immunosuppressive myeloid cells in the tumor microenvironment that contribute to drug resistance.
NRP Ratings Summary
NRP Quant Ranking